Wells Fargo & Company Increases BridgeBio Pharma (NASDAQ:BBIO) Price Target to $98.00

BridgeBio Pharma (NASDAQ:BBIO) had its price target lifted by Wells Fargo & Company from $88.00 to $98.00 in a report issued on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective points to a potential upside of 30.23% from the stock’s current price.

Several other research firms have also issued reports on BBIO. TD Cowen reiterated a “buy” rating on shares of BridgeBio Pharma in a research note on Monday, January 12th. Morgan Stanley began coverage on shares of BridgeBio Pharma in a report on Tuesday, January 6th. They set an “overweight” rating and a $96.00 price target for the company. Raymond James Financial set a $89.00 price objective on shares of BridgeBio Pharma and gave the stock an “outperform” rating in a research note on Thursday. Evercore reiterated an “outperform” rating on shares of BridgeBio Pharma in a research note on Monday, October 27th. Finally, Leerink Partners increased their price target on BridgeBio Pharma from $75.00 to $86.00 and gave the stock an “outperform” rating in a research report on Monday, December 15th. Twenty-two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $81.55.

BridgeBio Pharma Trading Down 1.1%

BBIO stock opened at $75.25 on Friday. BridgeBio Pharma has a 1-year low of $28.33 and a 1-year high of $84.94. The business’s 50 day moving average is $75.60 and its 200-day moving average is $63.20. The firm has a market cap of $14.50 billion, a P/E ratio of -18.00 and a beta of 1.13.

Insider Buying and Selling at BridgeBio Pharma

In other BridgeBio Pharma news, Director Andrew Lo sold 55,000 shares of the company’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $65.69, for a total transaction of $3,612,950.00. Following the transaction, the director directly owned 50,583 shares in the company, valued at approximately $3,322,797.27. This represents a 52.09% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Neil Kumar sold 40,000 shares of the firm’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $74.40, for a total transaction of $2,976,000.00. Following the completion of the transaction, the chief executive officer directly owned 775,686 shares in the company, valued at $57,711,038.40. This trade represents a 4.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 300,700 shares of company stock valued at $21,034,671 over the last ninety days. Company insiders own 18.20% of the company’s stock.

Hedge Funds Weigh In On BridgeBio Pharma

Several large investors have recently bought and sold shares of BBIO. Kestra Advisory Services LLC acquired a new stake in BridgeBio Pharma during the 4th quarter worth $235,000. FORA Capital LLC grew its stake in shares of BridgeBio Pharma by 62.2% during the fourth quarter. FORA Capital LLC now owns 18,035 shares of the company’s stock worth $1,397,000 after purchasing an additional 6,919 shares during the period. The Manufacturers Life Insurance Company increased its holdings in BridgeBio Pharma by 3.2% in the fourth quarter. The Manufacturers Life Insurance Company now owns 1,975,315 shares of the company’s stock valued at $151,012,000 after purchasing an additional 60,548 shares during the last quarter. Affinity Asset Advisors LLC lifted its stake in BridgeBio Pharma by 392.3% in the fourth quarter. Affinity Asset Advisors LLC now owns 320,000 shares of the company’s stock valued at $24,477,000 after buying an additional 255,000 shares during the period. Finally, Bridgewater Associates LP acquired a new position in BridgeBio Pharma in the fourth quarter valued at about $3,302,000. 99.85% of the stock is currently owned by institutional investors and hedge funds.

More BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: PROPEL 3 Phase‑3 topline: infigratinib met the primary endpoint (annualized height velocity) with a meaningful treatment difference vs. placebo, reported favorable safety, and BridgeBio plans NDA/MAA submissions in H2 2026 — a major de‑risking and commercialization step that drove earlier buying interest. Read More.
• Positive Sentiment: Analyst upgrades/target bumps: Wells Fargo raised its target to $98 (overweight) and Oppenheimer lifted its target to $83 (outperform). Those upgrades reinforced the commercial/regulatory narrative and supported the rally earlier in the week. Read More. Read More.
• Positive Sentiment: Competitive impact: BridgeBio’s positive data pressured rival programs (reports note BioMarin and Ascendis shares fell), suggesting BridgeBio may gain market share if approvals follow. Read More.
• Neutral Sentiment: Short‑interest reporting shows zero shares (likely a data or reporting glitch) and is not informative for positioning; ignore that metric until corrected by exchanges/data vendors.
• Negative Sentiment: Insider selling: CEO Neil Kumar sold 40,000 shares on Feb 10 (~$2.88M), part of a pattern of recent sales. That can prompt profit‑taking or investor concern about insider conviction despite large remaining holdings. Read More.
• Negative Sentiment: Near‑term financials remain a risk: Zacks flagged likely negative earnings in the upcoming report, keeping short‑term P&L and cash‑burn concerns on the table despite the clinical win. Read More.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.